Biotangents
Penicuik
About Biotangents
Biotangents was founded upon their Leapfrog Assembly™ platform technology for building complex genetic constructs from multiple DNA parts. This was developed through a SMART: Scotland award from Scottish Enterprise and was exe0mplified through the generation of their terpenoid biosynthesis strains. During that successful first year they also developed their DNA randomisation technology, Short Sequence Randomisation™. In 2016, having formulated a concept for a modular cell-free nucleic acid detection technology, Moduleic Sensing™, and with support from SynbiCITE, they commenced development of their first diagnostic test, a highly specific and sensitive solution for pen-side diagnosis of infectious diseases in livestock.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $10.0M
- Last round: Series Unknown (Nov 2024)
- Website: biotangents.co.uk
- Phone: 131 514 0871
Industries & Categories
Biotechnology, Chemical, Medical Device, Veterinary
Social Profiles
Canonical: https://fsome.com/organization/biotangents-3720 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.